


PRODUCT INFORMATION

URB602

Item No. 10007457



CAS Registry No.: 565460-15-3
Formal Name: N-[1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester
MF: C₁₉H₂₁NO₂
FW: 295.4
Purity: ≥98%
UV/Vis.: λ_{max}: 236 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

URB602 is supplied as a crystalline solid. A stock solution may be made by dissolving the URB602 in the solvent of choice, which should be purged with an inert gas. URB602 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of URB602 in ethanol is approximately 10 mg/ml and approximately 30 mg/ml in DMSO and DMF.

URB602 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, URB602 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. URB602 has a solubility of approximately 0.25 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

URB602 is a selective inhibitor of monoacylglycerol lipase (MAGL), exhibiting an IC₅₀ value of 28 μM for the rat brain enzyme.¹ It does not inhibit fatty acid amide hydrolase (FAAH) at concentrations up to 100 μM or other lipid metabolizing enzymes such as diacylglycerol lipase or COX-2.^{1,2} Inhibition of MAGL inhibits 2-arachidonoyl glycerol (Item No. 62160) hydrolysis, which is associated with enhanced stress-induced analgesia and may represent a novel drug target in pain and stress management.¹ URB602 (50 μM) also inhibits glucose-stimulated and depolarization-induced insulin secretion in INS-1 cells.³

References

1. Hohmann, A.G., Suplita, R.L., Bolton, N.M., *et al.* An endocannabinoid mechanism for stress-induced analgesia. *Nature* **435(7045)**, 1108-1112 (2005).
2. Tarzia, G., Duranti, A., Tontini, A., *et al.* Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. *J. Med. Chem.* **46(12)**, 2352-2360 (2003).
3. Berdan, C.S., Erion, K.A., Burritt, N.E., *et al.* Inhibition of monoacylglycerol lipase activity decreases glucose-stimulated insulin secretion in INS-1 (832/13) cells and rat islets. *PLoS One* **11(2)**, e0149008 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/18/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM